Jubilant Life Sciences, an integrated pharmaceuticals and life sciences company announced today that it has received a communication from the U.S. Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as 'Acceptable'.

This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications.

The development follows completion of FDA's review of the company's responses post the February letter and the subsequent re-inspection conducted at Jubilant's Montreal facility in September, 2013. This development successfully resolves the FDA issues at our Montreal facility.

Shares of the company gained Rs 7.8, or 6.69%, to trade at Rs 124.35. The total volume of shares traded was 61,310 at the BSE (9.40 a.m., Friday).